

# Elizabeth W Loder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7899628/publications.pdf>

Version: 2024-02-01

107  
papers

46,188  
citations

108046

37  
h-index

56606

87  
g-index

111  
all docs

111  
docs citations

111  
times ranked

30128  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Journal of Medical Economics</i> , 2022, 25, 1-7.	1.0	9
2	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>BMJ, The</i> , 2022, 376, e067975.	3.0	141
3	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Pharmacoeconomics</i> , 2022, 40, 601-609.	1.7	39
4	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. <i>Value in Health</i> , 2022, 25, 10-31.	0.1	251
5	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>BMC Public Health</i> , 2022, 22, 179.	1.2	7
6	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2022, , 1-10.	0.5	0
7	Equal Pay for Women Neurologists. <i>Neurology</i> , 2022, 98, 347-348.	1.5	0
8	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>BMC Health Services Research</i> , 2022, 22, 114.	0.9	5
9	Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e13.	0.2	78
10	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Value in Health</i> , 2022, 25, 3-9.	0.1	254
11	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>BMC Medicine</i> , 2022, 20, 23.	2.3	73
12	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 213.	1.0	12
13	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>European Journal of Health Economics</i> , 2022, 23, 1309-1317.	1.4	9
14	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2022, 28, 146-155.	0.5	3
15	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Clinical Therapeutics</i> , 2022, 44, 158-168.	1.1	22
16	Guidance relevant to the reporting of health equity in observational research: a scoping review protocol. <i>BMJ Open</i> , 2022, 12, e056875.	0.8	5
17	Identification of work accommodations and interventions associated with work productivity in adults with migraine: A scoping review. <i>Cephalgia</i> , 2021, 41, 760-773.	1.8	13
18	Effectiveness of Mindfulness Meditation vs Headache Education for Adults With Migraine. <i>JAMA Internal Medicine</i> , 2021, 181, 317.	2.6	87

#	ARTICLE	IF	CITATIONS
19	The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. <i>Headache</i> , 2021, 61, 60-68.	1.8	119
20	PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. <i>BMJ</i> , The, 2021, 372, n160.	3.0	3,413
21	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. <i>BMJ</i> , The, 2021, 372, n71.	3.0	26,066
22	The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. <i>PLoS Medicine</i> , 2021, 18, e1003583.	3.9	1,340
23	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. <i>Systematic Reviews</i> , 2021, 10, 89.	2.5	3,624
24	The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. <i>International Journal of Surgery</i> , 2021, 88, 105906.	1.1	3,487
25	Development of a checklist to detect errors in meta-analyses in systematic reviews of interventions: study protocol. <i>F1000Research</i> , 2021, 10, 455.	0.8	2
26	The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. <i>Journal of Clinical Epidemiology</i> , 2021, 134, 178-189.	2.4	995
27	Declaraci3n PRISMA 2020: una gu3a actualizada para la publicaci3n de revisiones sistem3ticas. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2021, 74, 790-799.	0.4	333
28	Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. <i>BMJ</i> , The, 2021, 375, n2233.	3.0	408
29	Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1614.	3.8	829
30	Pravila PRISMA 2020.. <i>Medicina Fluminensis</i> , 2021, 57, 444-465.	0.1	50
31	Medication overuse headache: The trouble with prevalence estimates. <i>Cephalalgia</i> , 2020, 40, 3-5.	1.8	5
32	Ten Eleven Things Not to Say to Healthcare Professionals During the Coronavirus Disease 2019 Pandemic. <i>Headache</i> , 2020, 60, 1837-1845.	1.8	5
33	Real-world effectiveness and tolerability of erenumab: A retrospective cohort study. <i>Cephalalgia</i> , 2020, 40, 1511-1522.	1.8	61
34	Awareness, usage and perceptions of authorship guidelines: an international survey of biomedical authors. <i>BMJ Open</i> , 2020, 10, e036899.	0.8	23
35	Disentangling placebo effects in the treatment of migraine. <i>Nature Reviews Neurology</i> , 2020, 16, 657-658.	4.9	4
36	Ten (No, Make that 11) Ways the Migraine Mavens Have Changed the Conversation About Sexism in Medicine. <i>Headache</i> , 2020, 60, 1042-1046.	1.8	0

#	ARTICLE	IF	CITATIONS
37	Addressing the Crisis of Diagnosis and Management of Migraine in Primary Care: A Summary of the American Headache Society FrontLine Primary Care Advisory Board. <i>Headache</i> , 2020, 60, 1000-1004.	1.8	9
38	Workforce Gap Analysis in the Field of Headache Medicine in the United States. <i>Headache</i> , 2020, 60, 478-481.	1.8	19
39	Characteristics of Neuropsychiatric Mobile Health Trials: Cross-Sectional Analysis of Studies Registered on ClinicalTrials.gov. <i>JMIR MHealth and UHealth</i> , 2020, 8, e16180.	1.8	1
40	Underrepresentation of Women Among Authors of Invited Commentaries in Medical Journals—Where Are the Female Editorialists?. <i>JAMA Network Open</i> , 2019, 2, e1913665.	2.8	19
41	Ten Eleven Things Not to Say to Your Female Colleagues. <i>Headache</i> , 2019, 59, 1846-1854.	1.8	12
42	Further Questioning of the Significance of the Gepants: A Response. <i>Headache</i> , 2019, 59, 1831-1831.	1.8	0
43	Time—™s up for he and him as the default pronouns for doctors. <i>BMJ, The</i> , 2019, 367, l6565.	3.0	0
44	Potential Benefits of Migraine—™What Is It Good For?. <i>JAMA Neurology</i> , 2019, 76, 250.	4.5	2
45	The Emperor—™s New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?. <i>Headache</i> , 2019, 59, 113-117.	1.8	45
46	Calcitonin Gene-Related Peptide Monoclonal Antibody Treatments for Migraine. <i>JAMA Internal Medicine</i> , 2019, 179, 421.	2.6	6
47	Consideration of Costs and Open-Label Studies of Erenumab—™Reply. <i>JAMA Neurology</i> , 2019, 76, 236.	4.5	3
48	Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome. <i>JAMA Neurology</i> , 2018, 75, 566.	4.5	64
49	The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies. <i>Headache</i> , 2018, 58, 496-505.	1.8	330
50	Risk of Stroke Associated With Use of Estrogen Containing Contraceptives in Women With Migraine: A Systematic Review. <i>Headache</i> , 2018, 58, 5-21.	1.8	65
51	Biomedical authors—™ awareness of publication ethics: an international survey. <i>BMJ Open</i> , 2018, 8, e021282.	0.8	12
52	Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process. <i>Headache</i> , 2018, 58, 1639-1657.	1.8	9
53	Who Should Try New Antibody Treatments for Migraine?. <i>JAMA Neurology</i> , 2018, 75, 1039.	4.5	24
54	Monoclonal Antibodies for Migraine Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1985.	3.8	14

#	ARTICLE	IF	CITATIONS
55	Migraine Pain Location and Measures of Healthcare Use and Distress: An Observational Study. <i>Pain Research and Management</i> , 2018, 2018, 1-11.	0.7	8
56	Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018. <i>Headache</i> , 2018, 58, 218-229.	1.8	41
57	Variation in Prescription Drug Coverage for Triptans: Analysis of Insurance Formularies. <i>Headache</i> , 2017, 57, 1243-1251.	1.8	4
58	The comorbidity burden of patients with cluster headache: a population-based study. <i>Journal of Headache and Pain</i> , 2017, 18, 76.	2.5	21
59	Medication overuse headache. <i>Neurology</i> , 2017, 89, 1296-1304.	1.5	58
60	Validity of cluster headache diagnoses in an electronic health record data repository. <i>Headache</i> , 2016, 56, 1132-1136.	1.8	8
61	A migraine management training program for primary care providers: An overview of a survey and pilot study findings, lessons learned, and considerations for further research. <i>Headache</i> , 2016, 56, 725-740.	1.8	38
62	Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2016, 56, 821-834.	1.8	160
63	Amitriptyline Dose and Treatment Outcomes in Specialty Headache Practice: A Retrospective Cohort Study. <i>Headache</i> , 2016, 56, 1626-1634.	1.8	23
64	Migraine diagnosis and treatment: A knowledge and needs assessment among primary care providers. <i>Cephalalgia</i> , 2016, 36, 358-370.	1.8	45
65	Headache Rounds: Sudden, Transient Neurologic Symptoms in a Woman With Migraine. <i>Headache</i> , 2015, 55, 1274-1282.	1.8	2
66	The Prevalence and Burden of Migraine and Severe Headache in the United States: Updated Statistics From Government Health Surveillance Studies. <i>Headache</i> , 2015, 55, 21-34.	1.8	405
67	The Prevalence, Burden, and Treatment of Severe, Frequent, and Migraine Headaches in US Minority Populations: Statistics From National Survey Studies. <i>Headache</i> , 2015, 55, 214-228.	1.8	82
68	Registration status and outcome reporting of trials published in core headache medicine journals. <i>Neurology</i> , 2015, 85, 1789-1794.	1.5	23
69	Adding NSAIDs to triptans: Could less be more?. <i>Cephalalgia</i> , 2014, 34, 407-408.	1.8	4
70	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) – Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. <i>Value in Health</i> , 2013, 16, 231-250.	0.1	1,657
71	The Prevalence, Impact, and Treatment of Migraine and Severe Headaches in the United States: A Review of Statistics From National Surveillance Studies. <i>Headache</i> , 2013, 53, 427-436.	1.8	319
72	Choosing Wisely in Headache Medicine: The American Headache Society's List of Five Things Physicians and Patients Should Question. <i>Headache</i> , 2013, 53, 1651-1659.	1.8	150

#	ARTICLE	IF	CITATIONS
73	Evaluation for Secondary Causes of Headache: The Role of Blood and Urine Testing. <i>Headache</i> , 2011, 51, 338-345.	1.8	19
74	The approach to the difficult patient. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2010, 97, 233-238.	1.0	2
75	Triptan Therapy in Migraine. <i>New England Journal of Medicine</i> , 2010, 363, 63-70.	13.9	178
76	Prophylaxis: Headaches That Never Happen. <i>Headache</i> , 2008, 48, 694-696.	1.8	6
77	Tension-type headache. <i>BMJ: British Medical Journal</i> , 2008, 336, 88-92.	2.4	52
78	Hormonal Management of Migraine Associated With Menses and the Menopause: A Clinical Review.. <i>Headache</i> , 2007, 47, 329-340.	1.8	38
79	Menstrual Migraine: Pathophysiology, Diagnosis, and Impact. <i>Headache</i> , 2006, 46, S55-S60.	1.8	18
80	Conclusion: How primary care physicians can help their patients with migraine. <i>The American Journal of Medicine: Supplement</i> , 2005, 118, 45-46.	1.7	0
81	Headache as a side effect of combination estrogen-progestin oral contraceptives: A systematic review. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 636-649.	0.7	81
82	General Principles of Migraine Management: The Changing Role of Prevention. <i>Headache</i> , 2005, 45, S33-S47.	1.8	61
83	Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo-controlled trial. <i>Current Medical Research and Opinion</i> , 2005, 21, 381-389.	0.9	35
84	Headache Attributed to Psychiatric Disorder: A Case Series. <i>Psychosomatics</i> , 2005, 46, 326-333.	2.5	9
85	Part II: Clinical efficacy and tolerability of zolmitriptan orally disintegrating tablet in the acute treatment of migraine. <i>Current Medical Research and Opinion</i> , 2005, 21, S8-S12.	0.9	7
86	Fixed Drug Combinations for the Acute Treatment of Migraine. <i>CNS Drugs</i> , 2005, 19, 769-784.	2.7	23
87	Off-Label Prescribing of Drugs in Specialty Headache Practice. <i>Headache</i> , 2004, 44, 636-641.	1.8	29
88	Migraine diagnosis and treatment. <i>Primary Care - Clinics in Office Practice</i> , 2004, 31, 277-292.	0.7	2
89	Who Will Prescribe? A Proposal for Specialized Opioid Management Clinics. <i>Pain Practice</i> , 2003, 3, 218-221.	0.9	0
90	Safety of Sumatriptan in Pregnancy. <i>CNS Drugs</i> , 2003, 17, 1-7.	2.7	62

#	ARTICLE	IF	CITATIONS
91	Use of Botulinum Toxins for Chronic Headaches: A Focused Review. <i>Clinical Journal of Pain</i> , 2002, 18, S169-S176.	0.8	47
92	Naratriptan in the Prophylaxis of Cluster Headache. <i>Headache</i> , 2002, 42, 56-57.	1.8	28
93	Volume and Nature of Telephone Calls in a Specialty Headache Practice. <i>Headache</i> , 2002, 42, 883-887.	1.8	16
94	A Pilot Study of Pain and Attitudes Toward Pain in a Rehabilitation Population. <i>Pain Medicine</i> , 2002, 3, 333-338.	0.9	3
95	Review: several drugs, especially triptans, are effective for pain relief in acute migraine. <i>ACP Journal Club</i> , 2002, 137, 103.	0.1	0
96	Review: Several drugs, especially triptans, are effective for pain relief in acute migraine. <i>ACP Journal Club</i> , 2002, 137, 103.	0.1	0
97	Mistaking primary headache for another condition. , 0, , 20-37.		0
98	When historical or examination findings are missed or misinterpreted. , 0, , 84-99.		0
99	Medicolegal pitfalls in headache management. , 0, , 175-185.		0
100	Missing dangerous causes of headache. , 0, , 38-53.		0
101	Pitfalls in diagnostic testing: imaging and lumbar puncture. , 0, , 54-72.		0
102	Errors in management of acute headache. , 0, , 100-118.		0
103	Pitfalls in diagnostic testing: blood, urine, and other tests. , 0, , 73-83.		0
104	Pitfalls in drug therapy to prevent headaches. , 0, , 119-144.		0
105	Pitfalls in nonpharmacologic treatment of headache. , 0, , 145-161.		0
106	Challenges and special situations in headache management. , 0, , 162-174.		0
107	Confusing one benign headache with another. , 0, , 1-19.		0